Who
Jason O'Byrne
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Olema Pharmaceuticals; EVP & Chief Financial Officer, Vir Biotechnology; Chief Financial Officer, Caribou Biosciences.
In numbers
- Trades disclosed
- 25
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $100K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 20 Dec 2021
- Last trade
- 1 Sep 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 2 Sep 2026 | OLMA Olema Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —650,000 at $0.00 | filing |
| 1 Sep 2026filed 2 Sep 2026 | OLMA Olema Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —650,000 at $0.00 | filing |
| 20 Mar 2026filed 23 Mar 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code J | —2,500 at $0.00 | filing |
| 20 Mar 2026filed 23 Mar 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code J | —2,500 at $0.00 | filing |
| 20 Mar 2026filed 23 Mar 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code J | —2,500 at $0.00 | filing |
| 20 Mar 2026filed 23 Mar 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code J | —2,500 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $16K1,634 at $9.53 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $16K1,634 at $9.53 | filing |
| 23 Feb 2026filed 24 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $16K2,089 at $7.45 | filing |
| 23 Feb 2026filed 24 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $16K2,089 at $7.45 | filing |
| 22 Feb 2026filed 24 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 22 Feb 2026filed 24 Feb 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 22 Feb 2026filed 24 Feb 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 22 Feb 2026filed 24 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 17 Nov 2025filed 18 Nov 2025 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $38K6,799 at $5.56 | filing |
| 22 Feb 2025filed 25 Feb 2025 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 22 Feb 2025filed 25 Feb 2025 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 15 Nov 2024filed 18 Nov 2024 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 15 Nov 2024filed 18 Nov 2024 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 20 Feb 2024filed 22 Feb 2024 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —153,000 at $0.00 | filing |
News
Vir Biotechnology (NASDAQ:VIR) Reaches New 12-Month High – Here's What HappenedVIR · tickerreport.com · 12 Oct 2026Vir Biotechnology (NASDAQ:VIR) vs. uniQure (NASDAQ:QURE) Critical ContrastVIR · dailypolitical.com · 11 Oct 2026Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $22.00VIR · tickerreport.com · 10 Oct 2026
0 headlines in the last 90 days name Jason O'Byrne; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.